Gilead Sciences (GILD) EV to CFO (2009 - 2026)
Gilead Sciences' (GILD) quarterly EV to CFO came in at 42.97 in Q2 2026, down 73.16% on a YoY basis from 160.1 in Q2 2025, and down 33.9% quarter-over-quarter from 65.0 in Q1 2026.
Analysis
Gilead Sciences (GILD) EV to CFO (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported EV to CFO for 18 consecutive years, with 42.97 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EV to CFO fell 73.16% year-over-year to 42.97; the trailing twelve-month figure through Jun 2026 stood at 11.33 (down 15.57% YoY), and the FY2025 full-year result was 14.43, up 48.81% from the prior year.
- EV to CFO slipped to 42.97 in Q2 2026 per GILD's latest filing, from 65.0 in the prior quarter.
- Across five years, EV to CFO topped out at 160.1 in Q2 2025 and bottomed at 23.05 in Q3 2024.
- Historically, EV to CFO has averaged 50.34 across 5 years, with a median of 41.41 in 2022.
- The sharpest annual moves came in 2025 and 2026: EV to CFO jumped 156.72% in 2025, then sank 73.16% in 2026.
- Over 5 years, EV to CFO stood at 39.2 in 2022, then increased by 10.06% to 43.15 in 2023, then slipped by 18.19% to 35.3 in 2024, then rose by 23.13% to 43.46 in 2025, then declined by 1.14% to 42.97 in 2026.
- According to Business Quant data, EV to CFO over the past three periods registered 42.97, 65.0, and 43.46 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 42.97 |
| Mar 31, 2026 | 65.00 |
| Dec 31, 2025 | 43.46 |
| Sep 30, 2025 | 31.75 |
| Jun 30, 2025 | 160.10 |
| Mar 31, 2025 | 74.84 |
| Dec 31, 2024 | 35.30 |
| Sep 30, 2024 | 23.05 |
| Jun 30, 2024 | 62.36 |
| Mar 31, 2024 | 38.97 |
| Dec 31, 2023 | 43.15 |
| Sep 30, 2023 | 49.30 |
| Jun 30, 2023 | 38.23 |
| Mar 31, 2023 | 55.97 |
| Dec 31, 2022 | 39.20 |
| Sep 30, 2022 | 25.04 |
| Jun 30, 2022 | 39.86 |
| Mar 31, 2022 | 37.65 |
| Dec 31, 2021 | 26.37 |
| Sep 30, 2021 | 25.18 |